An Overview of the H5N1 mRNA Vaccine Pipeline.
作者信息
Focosi Daniele, Nicastri Emanuele, Maggi Fabrizio
机构信息
North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.
National Institute for Infectious Diseases "Lazzaro Spallanzani", Rome, Italy.
出版信息
Influenza Other Respir Viruses. 2025 May;19(5):e70113. doi: 10.1111/irv.70113.
Abstract
摘要
相似文献
1
An Overview of the H5N1 mRNA Vaccine Pipeline.H5N1 mRNA疫苗研发进展概述。
Influenza Other Respir Viruses. 2025 May;19(5):e70113. doi: 10.1111/irv.70113.
2
Low-inflammatory lipid nanoparticle-based mRNA vaccine elicits protective immunity against H5N1 influenza virus with reduced adverse reactions.低炎症性基于脂质纳米颗粒的mRNA疫苗可诱导针对H5N1流感病毒的保护性免疫，且不良反应减少。
Mol Ther. 2025 Feb 5;33(2):529-547. doi: 10.1016/j.ymthe.2024.12.032. Epub 2024 Dec 17.
3
An influenza mRNA vaccine protects ferrets from lethal infection with highly pathogenic avian influenza A(H5N1) virus.一种流感mRNA疫苗可保护雪貂免受高致病性甲型禽流感病毒A(H5N1)的致命感染。
Sci Transl Med. 2024 Dec 18;16(778):eads1273. doi: 10.1126/scitranslmed.ads1273.
4
R848 Adjuvant Laden With Self-Assembled Nanoparticle-Based mRNA Vaccine Elicits Protective Immunity Against H5N1 in Mice.R848 佐剂负载自组装纳米颗粒基于 mRNA 疫苗诱导小鼠抗 H5N1 的保护性免疫。
Front Immunol. 2022 May 31;13:836274. doi: 10.3389/fimmu.2022.836274. eCollection 2022.
5
A systematic review and meta-analysis of cross-reactivity of antibodies induced by oil-in-water emulsion adjuvanted influenza H5N1 virus monovalent vaccines.水包油乳剂佐剂H5N1流感病毒单价疫苗诱导抗体的交叉反应性的系统评价与荟萃分析
Vaccine. 2017 May 31;35(24):3162-3170. doi: 10.1016/j.vaccine.2017.04.029. Epub 2017 May 5.
6
Comparative safety, immunogenicity, and efficacy of several anti-H5N1 influenza experimental vaccines in a mouse and chicken models (Testing of killed and live H5 vaccine).几种抗 H5N1 流感实验疫苗在小鼠和鸡模型中的比较安全性、免疫原性和有效性（灭活和活 H5 疫苗的测试）。
Influenza Other Respir Viruses. 2012 May;6(3):188-95. doi: 10.1111/j.1750-2659.2011.00291.x. Epub 2011 Sep 23.
7
Cross-Protection by Inactivated H5 Prepandemic Vaccine Seed Strains against Diverse Goose/Guangdong Lineage H5N1 Highly Pathogenic Avian Influenza Viruses.灭活 H5 疫苗种株对不同鸭/广东谱系 H5N1 高致病性禽流感病毒的交叉保护作用。
J Virol. 2020 Nov 23;94(24). doi: 10.1128/JVI.00720-20.
8
H5N1 vaccine-specific B cell responses in ferrets primed with live attenuated seasonal influenza vaccines.用减毒活季节性流感疫苗免疫的雪貂体内H5N1疫苗特异性B细胞反应
PLoS One. 2009;4(2):e4436. doi: 10.1371/journal.pone.0004436. Epub 2009 Feb 11.
9
Avian influenza mRNA vaccine encoding hemagglutinin provides complete protection against divergent H5N1 viruses in specific-pathogen-free chickens.编码血凝素的禽流感信使核糖核酸疫苗为无特定病原体鸡提供针对不同H5N1病毒的完全保护。
J Nanobiotechnology. 2025 Jan 29;23(1):55. doi: 10.1186/s12951-025-03156-w.
10
Immunoinformatic based designing of potential immunogenic novel mRNA and peptide-based prophylactic vaccines against H5N1 and H7N9 avian influenza viruses.基于免疫信息学的设计针对 H5N1 和 H7N9 禽流感病毒的新型潜在免疫原性 mRNA 和基于肽的预防性疫苗。
J Biomol Struct Dyn. 2024 Apr;42(7):3641-3658. doi: 10.1080/07391102.2023.2214228. Epub 2023 May 24.
本文引用的文献
1
An overview of influenza H5 vaccines.H5型流感疫苗概述。
Lancet Respir Med. 2025 Apr;13(4):e20-e21. doi: 10.1016/S2213-2600(25)00052-9. Epub 2025 Mar 13.
2
Global production capacity of seasonal and pandemic influenza vaccines in 2023.2023年季节性流感疫苗和大流行流感疫苗的全球生产能力。
Vaccine. 2025 Apr 2;51:126839. doi: 10.1016/j.vaccine.2025.126839. Epub 2025 Feb 18.
3
sa-mRNA influenza vaccine raises a higher and more durable immune response than mRNA vaccine in preclinical models.在临床前模型中，自扩增mRNA流感疫苗比mRNA疫苗引发更高且更持久的免疫反应。
Vaccine. 2025 Apr 2;51:126883. doi: 10.1016/j.vaccine.2025.126883. Epub 2025 Feb 16.
4
Clade 2.3.4.4b but not historical clade 1 HA replicating RNA vaccine protects against bovine H5N1 challenge in mice.进化枝2.3.4.4b而非历史进化枝1的血凝素（HA）复制型RNA疫苗可保护小鼠免受牛源H5N1病毒的攻击。
Nat Commun. 2025 Jan 14;16(1):655. doi: 10.1038/s41467-024-55546-7.
5
Advancement in the development of mRNA-based vaccines for respiratory viruses.mRNA 疫苗在呼吸道病毒研发中的进展。
Immunology. 2024 Nov;173(3):481-496. doi: 10.1111/imm.13844. Epub 2024 Aug 19.
6
Advances in the design and delivery of RNA vaccines for infectious diseases.传染病 RNA 疫苗的设计与递送的新进展。
Adv Drug Deliv Rev. 2024 Oct;213:115419. doi: 10.1016/j.addr.2024.115419. Epub 2024 Aug 5.
7
Resources, Production Scales and Time Required for Producing RNA Vaccines for the Global Pandemic Demand.为满足全球大流行需求生产RNA疫苗所需的资源、生产规模和时间。
Vaccines (Basel). 2020 Dec 23;9(1):3. doi: 10.3390/vaccines9010003.
8
Quantitative variation in plasma angiotensin-I converting enzyme activity shows allelic heterogeneity in the ABO blood group locus.血浆血管紧张素-I转换酶活性的定量变异在ABO血型位点显示出等位基因异质性。
Ann Hum Genet. 2013 Nov;77(6):465-71. doi: 10.1111/ahg.12034. Epub 2013 Aug 13.
Zotero 插件